ClinicalTrials.gg
RecruitingNCT07518472Updated Apr 8, 2026

Additional Effects of Box Breathing Technique With Short Term Pulmonary Rehabilitation on Dyspnea and Functional Capacity in Patients With Chronic Obstructive Pulmonary Disease

An interventional study of Short term Pulmonary Rehabilitation and Box breathing with short term pulmonary rehabilitation in Pulmonary Disease, Chronic Obstructive (COPD), sponsored by Foundation University Islamabad. Recruiting at 1 site in Pakistan. Open to participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-08.

Primary conditionPulmonary Disease, Chronic ObstructiveRegistry: Lung DiseasesReclassifiedWhy we changed it
Registry
Lung Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pulmonary Disease, Chronic Obstructive
Why
  1. The study's listed conditions name Pulmonary Disease, Chronic Obstructive, a narrower term within Lung Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Foundation University Islamabad · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Feb 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 78 studies in Pulmonary Disease, Chronic Obstructive with a site in Pakistan — 28 open to participants now, 28 under way, 1 of them phase 3. Pulmonary Disease, Chronic Obstructive · Pakistan.

Planned enrollment
52nd of 75
40 · median 48
Started
2026
with 11 others
No phase
72 of 78
27 open now
Primary completion
2026-05
later than 17 of 27 live
Registered
68th of 78
by date
Lead sponsor
6 of 78
Foundation University Islamabad

Among the 78 studies in Pulmonary Disease, Chronic Obstructive with a site in Pakistan, this one is the 52nd largest by planned enrollment of the 75 interventional ones that give a count, is one of 12 that started in 2026, is one of 72 with no phase, reaches primary completion later than 17 of the 27 other live ones, and was the 68th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

28 of the 78 studies in Pulmonary Disease, Chronic Obstructive with a site in Pakistan are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Pulmonary Disease, Chronic Obstructive with a site in Pakistan, or all of them as a file.
02

Study summary

Chronic Obstructive Pulmonary Disease is progressive and irreversible respiratory condition characterized by persistent airflow limitation leading to dyspnea and reduced functional capacity.

Pulmonary rehabilitation along with different technqiues of breathing exercises reduces dyspnea and enhance functional capacity by improving ventilatory efficiency, respiratory muscle control and overall exercise tolerance in patients with COPD.

Read the detailed description

Chronic Obstructive pulmonary Disease is a progressive and irreversible respiratory condition characterized by persistent airflow limitation leading to dyspnea and reduced functional capacity.

Pulmonary Rehabilitation, a cornerstone in COPD management helps to reduce dyspnea and improve functional capacity. Although long-term PR programs yield sustained benefits, shorter-duration PR (e.g., 3-week interventions) may offer greater feasibility and higher patient adherence.

Total 40 participants will be allocated into two groups. Group A will be provided with short term Pulmonary rehabilitation along with pharmacological management and group B will be given additional Box breathing along with short term pulmonary rehabilitation The objective of this study is to determine the additional effects of Box breathing technique with short term pulmonary rehabilitation versus short term pulmonary rehabilitation alone on Dyspnea, Functional capacity and quality of life in patients with chronic obstructive pulmonary disease.

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive (COPD)

Browse trials for

Keywords

  • COPD
  • Short term pulmonary rehabilitation
  • box breathing
  • dyspnea
  • functional capacity
04

In context

Pulmonary Disease, Chronic Obstructive Reclassified

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

This study's planned enrollment of 40 is below the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.

Browse Pulmonary Disease, Chronic Obstructive studies →

Lead sponsor

Foundation University Islamabad is the lead sponsor of 255 studies on the registry; 142 are open to participants now.

Compared within Pulmonary Disease, Chronic Obstructive, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 40-65 years
  • Both genders (male and female)
  • Grade 1-3 on mMRC scale of dyspnea
  • mild stage according to global initiative for chronic obstructive lung -disease (GOLD) classification; Mild = greater than or equal to 80% predicted

Exclusion criteria

Exclusion Criteria:

  • Patients having acute exerbation of
  • Patients diagnosed with acute infection (pmeumonia, T.B)
  • Any orthopedic or neuromuscular condition that hinders participation in exercise training program
  • Patients unable to follow command and instructions
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Short term pulmonary rehabilitation

    Patients in this group will receive Short term pulmonary rehabilitation along with pharmacological management. Two sessions per week, supervised by physiotherapist will be conducted for a total of 3 weeks.

    Other: Short term Pulmonary Rehabilitation

  • Experimental
    Box breathing with short term pulmonary rehabilitation

    Patients in this group will receive Box breathing as well as short term pulmonary rehabilitation along with pharmacological management. Two sessions per weeek, supervised by physiotherapist will be conducted for a total of 3 weeks. In Group B, box breathing will be performed daily. A home diary will be provided in order to ensure and follow-up that the participants are performing breathing exercise at home.

    Other: Box breathing with short term pulmonary rehabilitation

Interventions

  • OtherShort term Pulmonary Rehabilitation

    Patients in this group will receive short term pulmonary rehabilitation along with pharmacological management. A total of 3 weeks protocol will be followed in which 2 seesions per week will be supervised by physiotherapist. Short term pulmonary rehabilitation includes: Warm-up(5-7min): light walking Aerobic training: mild-moderate intensity (40-60% of MHR) cycling or walk on treadmill/over ground Strength training: Exercises for major muscle groups (upper limb, lower limb and trunk) using body weight based on 1RM. Upper limb: upright row, shoulder press, bicep curls Lower limb: sit-to-stand, mini knee lifts, 3 steps calf raises Core: Seated abdominal contraction, back extension Perform 1-2 sets of 5-10 repetitions for each exercise, resting 1-2 mins between sets. Breathing exercise: pursed-lip breathing (1-3 sets of 5-10 reps) Cool down: (5-10min) Pharmacological management: Patient will receive medications as per prescribed by pulmonologist

  • OtherBox breathing with short term pulmonary rehabilitation

    Patients in this group will receive box breathing with short term pulmonary rehabilitation along with pharmacological management. A total 3 weeks protocol will be followed in which 2 sessions per week will be supervised by physiotherapist and box breathing will be performed daily. Patient will receive short term pulmonary rehabilitation including: Warm -up (5-7 min): light walking Aerobic training: mild-moderate intensity (40-60%of MHR) cycling or walk on treadmill/over ground. Strength training: Exercises for major muscle groups (upper limb, lower limb and trunk) using body weight based on 1RM. Upper limb: upright row, shoulder press, bicep curls Lower limb: sit-to-stand, mini knee lifts, 3 steps calf raises Core: seated abdominal contractions, back extensions Perform 1-2 sets of 5-10 repetitions for each exercise resting 1-2 min between sets. Breathing exercise: pursed-lip breathing (1-3 sets of 5 -10 repetitions) Cool down: (5-10 min) Box breathing: The patient will be instructed

07

What researchers measure

Primary outcomes

  1. Dyspnea

    Evaluation will be performed using the Modified Medical Research Council (mMRC) Dyspnea Scale, a clinician-administered scale ranging from 0 to 4, where: 0 indicates breathlessness only with strenuous exercise 4 indicates severe breathlessness (too breathless to leave the house or breathless while dressing) Higher scores represent worse dyspnea severity and poorer functional status.

    Time frame: 03 weeks

Secondary outcomes

  1. Functional Capacity

    Evaluation will be done by using 6 minute walk test

    Time frame: 03 weeks

08

Study locations

1 of 1 sites recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for May 2026, 2 months after the start.

Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 2 months is below that.

Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2026
First posted
Apr 8, 2026
StartActual
Feb 28, 2026
Primary completionEst.
May 15, 2026
CompletionEst.
May 15, 2026
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07518472
Responsible party
Sponsor
First posted
Apr 8, 2026
Start date
Feb 28, 2026
Primary completion
May 15, 2026 (estimated)
Completion
May 15, 2026 (estimated)
Last update
Apr 8, 2026

Study contacts

Fanila Tamdeen, MSPT-CPT
Contact
fanilatamdeen69@gmail.com
+923185085604
Zara Khalid, PhD
Contact
zara.khalid@fui.edu.pk
+92333-5415822

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion